References
- Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest 2009; 39: 699-706. 10.1111/j.1365-2362.2009.02162.x
- Jiang H, Tian Y, Yan W, Kong Y, Wang H, Wang A, et al. The prevalence of thyroid nodules and an analysis of related lifestyle factors in Beijing communities. Int J Environ Res Public Health 2016; 13: 1-11. 10.3390/ijerph13040442
- Remonti LR, Kramer CK, Leitao CB, Pinto LCF, Gross JL. Thyroid ultrasound features and risk of carcinoma: a systematic review and meta-analysis of observational studies. Thyroid 2015; 25: 538-50. 10.1089/thy.2014.0353
- Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab 2006; 91: 3411-17. 10.1210/jc.2006-0690
- Welker MJ, Orlov D. Thyroid nodules. Am Fam Physician 2003; 67: 559-66; 573.
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29. 10.3322/caac.21208
- Crowe A, Linder A, Hameed O, Salih C, Roberson J, Gidley J, et al. The impact of implementation of the Bethesda System for Reporting Thyroid Cytopathology on the quality of reporting, ‘risk’ of malignancy, surgical rate, and rate of frozen sections requested for thyroid lesions. Cancer Cytopathol 2011; 119: 315-21. 10.1002/cncy.20174
- Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. J Am Soc Cytopathol 2017; 6: 217-22. 10.1016/j.jasc.2017.09.002
- Gweon HM, Son EJ, Youk JH, Kim JA. Thyroid nodules with Bethesda system III cytology: can ultrasonography guide the next step? Ann Surg Oncol 2013; 20: 3083-8. 10.1245/s10434-013-2990-x
- Ho AS, Sarti EE, Jain KS, Wang H, Nixon IJ, Shaha AR, et al. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid 2014; 24: 832-9. 10.1089/thy.2013.0317
- Ryu YJ, Jung YS, Yoon HC, Hwang MJ, Shin SH, Cho JS, et al. Atypia of undetermined significance on thyroid fine needle aspiration: surgical outcome and risk factors for malignancy. Ann Surg Treat Res 2014; 86: 109. 10.4174/astr.2014.86.3.109
- Jeong SH, Sook HH, Lee EH. Outcome of Bethesda III thyroid nodules and its correlation with ultrasonographic features and BRAF. Poster presented at European Congress of Radiology; 2013 March 7-11; Vienna, Austria. No. C-0842. 10.1594/ecr2013/C-0842
- Yoo MR, Gweon HM, Park AY, Cho KE, Kim J, Youk JH, et al. Repeat diagnoses of Bethesda category III thyroid nodules: what to do next? PLoS One 2015; 10: 1-10. 10.1371/journal.pone.0130138
- Nagarkatti SS, Faquin WC, Lubitz CC, Garcia DM, Barbesino G, Ross DS, et al. The management of thyroid nodules with atypical cytology on fine needle aspiration biopsy. Ann Surg Oncol 2013; 20: 1-13. 10.1245/s10434-012-2601-2
- Vanderlaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol 2011; 136: 572-7. 10.1309/AJCPO0BQ2YSKPXXP
- Godazandeh G, Kashi Z, Zargamataj S, Fazli M, Ebadi R, Kerdabadi EH, et al. Evaluation the relationship between thyroid nodule size with malignancy and accuracy of fine needle aspiration biopsy (FNAB). Acta Inform Medica 2016; 24: 347-51. 10.5455/aim.2016.24.347-351
- McHenry CR, Huh ES, Machekano RN. Is nodule size an independent predictor of thyroid malignancy? Surgery 2018; 144: 1062-9. 10.1016/j.surg.2008.07.021
- Kamran SC, Marqusee E, Kim M, Frates M, Ritner J, Peters H, et al. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab 2013; 98: 564-70. 10.1210/jc.2012-2968
- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1-133. 10.1089/thy.2015.0020
- Mirfakhraee S, Mathews D, Peng L, Woodruff S, Zigman JM. A solitary hyperfunctioning thyroid nodule harboring thyroid carcinoma: review of the literature. Thyroid Res 2013; 6: 7. 10.1186/1756-6614-6-7
- Kwak JY. Indications for fine needle aspiration in thyroid nodules. Endocrinol Metab 2013; 28: 81-5. 10.3803/EnM.2013.28.2.81
- Lingam RK, Qarib MH, Tolley NS. Evaluating thyroid nodules: Predicting and selecting malignant nodules for fine-needle aspiration (FNA) cytology. Insights Imaging 2013; 4: 617-24. 10.1007/s13244-013-0256-6
- Moon WJ, Baek JH, Jung SL, Kim DW, Kim EK, Kwak JY, et al. Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol 2011; 12: 1-14. 10.3348/kjr.2011.12.1.1
- Khadra H, Bakeer M, Hauch A, Hu T, Kandil E. Is vascular flow a predictor of malignant thyroid nodules? A meta-analysis. Gland Surg 2016; 5: 576-82. 10.21037/gs.2016.12.14
- Maia F, Zantut-Wittmann D. Thyroid nodule management: clinical, ultrasound and cytopathological parameters for predicting malignancy. Clinics 2012; 67: 945-54. 10.6061/clinics/2012(08)15
- Ohori N, Nikiforova M, Schoedel K, Lebeau S, Hodak S, Seethala RR, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of ‘follicular lesion of undetermined significance/atypia of undetermined significance’. Cancer Cytopathol 2010; 118: 17-23. 10.1002/cncy.20063
- Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94: 2092-8. 10.1210/jc.2009-0247
- Su X, Jiang X, Xu X, Wang W, Teng X, Shao A, et al. Diagnostic value of BRAF (V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis. Onco Targets Ther 2016; 9: 2495-509. 10.2147/OTT.S101800